CLDX
$2.13
Celldex Therapeutics
CLDX
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  ($0.93)
Revenue:  $0.63 Mil
Tuesday
Feb 11
After the close
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CLDX reports earnings?
Beat
Meet
Miss

Where is CLDX's stock price going from here?
Up
Flat
Down
Stock chart of CLDX
Analysts
Summary of analysts' recommendations for CLDX
Score
Grade
Pivots
Resistance
$2.50
$2.43
$2.28

$2.21

Support
$2.06
$1.99
$1.84
Tweet
Growth
Description
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
Peers
Myriad GeneticsImmunomedicsQuidelCareDxMeridian BioscienceSurModics